For example, we have observed that pharmacologic stimulation of Kv11.1 with the selective activator NS1643 in various breast cancer cells results in marked decrease in cell proliferation by activation of a senescent-like cellular program that is characterized by a cell cycle arrest at G1 phase, decreased levels of tumor markers such as cyclin E2 and increased level of tumor suppressors such as p21Waf1/Cip1 and p16INK4A [48,169]. This evidence concerns the gene KCNH2 and neoplasm.